Category: cancer biology

Cancer researcher has dodged accusations for decades (and has a new correction)

Today isn’t a great day for Carlo Croce, chair of the department of cancer biology and genetics at The Ohio State University (OSU).

The New York Times has a lengthy article detailing the misconduct accusations that have swirled around Croce for years. We’ve covered many, but The Gray Lady obtained documents that show there have been many more.

The story mentions a 2013 letter from Ohio State University to pseudonymous whistleblower Clare Francis (which we reported on in 2014), acknowledging Francis’s allegations against Croce. However, in the letter, an administrator said OSU saw no reason to investigate Croce.

The story didn’t stop there, as the Times reports:

Continue reading Cancer researcher has dodged accusations for decades (and has a new correction)

3rd retraction appears for fired Pfizer breast cancer researcher

Pfizer has retracted a paper by a former employee who was fired after the company discovered she had been doctoring data.

The retraction, in Molecular Cancer Research, is the third of five papers Pfizer asked to retract, after an investigation discovered they contained duplicated images. The papers have been discussed on PubPeer, which is also mentioned in the latest retraction notice.

As a result of the investigation, Pfizer terminated the employment of Min-Jean Yin, the last author on the newly retracted paper.

According to the notice, Yin and five of her co-authors agreed to the retraction:

Continue reading 3rd retraction appears for fired Pfizer breast cancer researcher

Cancer biologist stops research as his retraction count rises to 13

Anil Jaiswal

A cancer biologist based at the University of Maryland is transitioning out of research, as a journal has retracted three more of his papers.

Anil Jaiswal has now lost 13 papers, including, as we reported on February 6, six retractions issued earlier this month.

The Baltimore Sun reported this week that Jaiswal would no longer be conducting research at the University of Maryland School of Medicine, which we confirmed from a spokesperson:

Continue reading Cancer biologist stops research as his retraction count rises to 13

Cancer researcher logs 6 retractions, bringing total to 10

Anil Jaiswal

A journal has retracted six papers by a cancer researcher at the University of Maryland in Baltimore, bringing his total to 10.

The retractions cite an investigation by the university, and detail problems ranging from duplicated images, to tweaking an image to conceal particular bands, to including unreliable data.

Three of the papers had already been flagged by the journal with expressions of concern. The last author on all the papers is Anil Jaiswal, a professor in the pharmacology department. He has issued four previous retractions.

Bruce Jarrell, the Chief Academic and Research Officer and Senior Vice President at the University of Maryland, told us at least two more retractions are forthcoming:

Continue reading Cancer researcher logs 6 retractions, bringing total to 10

“We made big mistakes:” Gastric paper pulled with unusual notice

Sometimes we come across a real head-scratcher.

That happened this week, when we saw a retraction notice for a 2015 paper on gastric cancer in the International Journal of Clinical and Experimental Medicine, which only says the authors “made big mistakes” and contains two fairly significant typos.

Although there’s no sign of a retraction on PubMed, the table of contents for the latest issue of the journal lists the retraction — but includes no hyperlink to the notice. The only way to see it is via a Web cached version. Here’s the text:

Continue reading “We made big mistakes:” Gastric paper pulled with unusual notice

What turned a cancer researcher into a literature watchdog?

Jennifer Byrne

Sometime in the middle of 2015, Jennifer Byrne, professor of molecular oncology at the University of Sydney, began her journey from cancer researcher to a scientific literature sleuth, seeking out potentially problematic papers.

The first step was when she noticed several papers that contained a mistake in a DNA construct which, she believed, meant the papers were not testing the gene in question, associated with multiple cancer types.  She started a writing campaign to the journal editors and researchers, with mixed success. But less than two years later, two of the five papers she flagged have already been retracted.

When asked why she spent time away from bench research to examine this issue, Byrne told us:  Continue reading What turned a cancer researcher into a literature watchdog?

At last, cancer reproducibility project releases some results — and they’re mixed

Nearly five years ago, researchers suggested that the vast majority of preclinical cancer research wouldn’t hold up to follow-up experiments, delaying much needed treatments for patients. In a series of articles publishing tomorrow morning, eLife has released the results of the first five attempts to replicate experiments in cancer biology — and the results are decidedly mixed.

As our co-founders Adam Marcus and Ivan Oransky write in STAT, the overall take-home message was that two studies generated findings similar to the original, one did not replicate the original, and two others were inconclusive.

They quote Brian Nosek, a psychologist at the University of Virginia, in Charlottesville, who runs the Center for Open Science, who has been leading the replication effort in his own field:

Continue reading At last, cancer reproducibility project releases some results — and they’re mixed

Breast cancer studies by fired Pfizer employee retracted

Last year, Pfizer fired one of its scientists following an investigation that ended with requests for retraction of five of her studies. Now, two of the five papers, which were first flagged on PubPeer, have been retracted.

One notice cites the Pfizer investigation, which found that cancer researcher Min-Jean Yin had included duplicated images in all five papers. Yin is the last author on both retracted papers.

Here’s the first notice from Clinical Cancer Research, which says most or all of the questioned images appear to be duplicates, and Pfizer — who sponsored the study and requested the retraction — can’t find the originals:
Continue reading Breast cancer studies by fired Pfizer employee retracted

Journal retracts gastric cancer study with multiple duplications, authors MIA

An oncology journal has decided to retract a 2012 paper on gastric cancer after discovering duplicated data in multiple figures.

According to the retraction notice, the journal’s editorial board received a tip from a reader regarding the potential figure issues. Oncology Reports launched an investigation, which confirmed the allegations. The authors failed to respond to the journal’s multiple requests for more information.

Here’s the retraction notice: Continue reading Journal retracts gastric cancer study with multiple duplications, authors MIA

Cancer researcher in Germany loses multiple papers after misconduct finding

A pathology journal is retracting two papers after an investigation at the last author’s institution in Germany found evidence of scientific misconduct.

The notice for both papers cites an investigation involving Regine Schneider-Stock, who studies cancer biology at the Friedrich Alexander-University Erlangen-Nuremberg (FAU). Meanwhile, another 2005 paper that lists Schneider-Stock as the first author was retracted in October, noting evidence of image manipulation.

The most recent retractions, from the American Journal of Pathology, note that FAU declined to provide the journal with details of its investigation beyond a prepared statement:

Continue reading Cancer researcher in Germany loses multiple papers after misconduct finding